Phase 3 study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001; trial in progress)

被引：0

作者：

Powles, T. ^{[1
]}

Grande, E. ^{[2
]}

Van Der Heijden, M. ^{[3
]}

Necchi, A. ^{[4
]}

Iyer, G. ^{[5
]}

Drakaki, A. ^{[6
]}

Loriot, Y. ^{[7
]}

Sokolowski, K. ^{[8
]}

Zhang, W. ^{[9
]}

Galsky, M. ^{[10
]}

机构：

[1] Barts Hlth NHS Trust, Barts Canc Ctr, London, England

[2] MD Anderson Madrid Canc Ctr, Med Oncol Program, Madrid, Spain

[3] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands

[4] Univ Vita Salute San Raffaele, Dept Genitourinary Med Oncol, IRCCS San Raffaele Hosp & Sci Inst, Milan, Italy

[5] Mem Sloan Kettering Canc Ctr, Dept Oncol, 1275 York Ave, New York, NY 10021 USA

[6] David Geffen Sch Med, Dept Hematol Oncol & Urol, Los Angeles, CA USA

[7] Inst Cancerol Gustave Roussy, Dept Med Oncol, Villejuif, France

[8] Seagen Inc, Late Stage Clin Dev, Bothell, WA USA

[9] Seagen Inc, Dept Stat, Bothell, WA USA

[10] Icahn Sch Med Mt Sinai, Dept Genitourinary Med Oncol, New York, NY 10029 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

A0746

引用

页码：S1721 / S1721

页数：1